Tag: segment

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

Singapore, July 01, 2025 (GLOBE NEWSWIRE) -- Origin Investment Corp I (the “Company”), a blank check company, today announced the pricing of its initial public offering (“IPO”) of 6,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. The units are expected to begin trading on the Nasdaq Global Market (“Nasdaq”) on July 2, 2025 under the ticker symbol “ORIQU”. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as described in the prospectus. Only whole warrants are exercisable. The warrants will become exercisable 30 days after the completion of the Company’s initial business combination, and will expire five years after the completion of the Company’s initial business combination or earlier upon redemption or the Company’s liquidation. The offering is expected to close on July 3, 2025, subject to satisfaction of customary closing conditions. Once the securities comprising the units begin separate trading, the Class A ordinary shares and the warrants are expected to be traded on Nasdaq under the symbols “ORIQ” and “ORIQW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. In addition, the Company has granted the underwriters a 45-day option to purchase up to 900,000 additional units at the IPO price to cover over-allotments, if any.

HOUSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Occidental (NYSE: OXY) will announce its second quarter 2025 financial results after close of market on Wednesday, August 6, 2025, and will hold a conference call to discuss the results on Thursday, August 7, 2025, at 1 p.m. Eastern/12 p.m. Central.

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.